JP5227034B2 - チミジンキナーゼ活性の測定のための方法およびキットならびにその使用 - Google Patents
チミジンキナーゼ活性の測定のための方法およびキットならびにその使用 Download PDFInfo
- Publication number
- JP5227034B2 JP5227034B2 JP2007556999A JP2007556999A JP5227034B2 JP 5227034 B2 JP5227034 B2 JP 5227034B2 JP 2007556999 A JP2007556999 A JP 2007556999A JP 2007556999 A JP2007556999 A JP 2007556999A JP 5227034 B2 JP5227034 B2 JP 5227034B2
- Authority
- JP
- Japan
- Prior art keywords
- kinase
- activity
- ndk
- assay kit
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000006601 Thymidine Kinase Human genes 0.000 title claims abstract description 103
- 108020004440 Thymidine kinase Proteins 0.000 title claims abstract description 103
- 230000000694 effects Effects 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 claims abstract description 51
- 210000004027 cell Anatomy 0.000 claims abstract description 39
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 26
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 26
- 238000003149 assay kit Methods 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 210000002966 serum Anatomy 0.000 claims abstract description 22
- 239000000758 substrate Substances 0.000 claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 239000000872 buffer Substances 0.000 claims abstract description 19
- 239000007787 solid Substances 0.000 claims abstract description 16
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 claims abstract description 15
- 239000002777 nucleoside Substances 0.000 claims abstract description 13
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 12
- 239000002773 nucleotide Substances 0.000 claims abstract description 12
- 239000011541 reaction mixture Substances 0.000 claims abstract description 12
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 11
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 10
- 239000010452 phosphate Substances 0.000 claims abstract description 10
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims abstract description 8
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229950004398 broxuridine Drugs 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 6
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims abstract description 6
- 238000004393 prognosis Methods 0.000 claims abstract description 6
- 238000012216 screening Methods 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 229940000406 drug candidate Drugs 0.000 claims abstract description 5
- 229960004716 idoxuridine Drugs 0.000 claims abstract description 5
- 230000000379 polymerizing effect Effects 0.000 claims abstract description 5
- 210000001519 tissue Anatomy 0.000 claims abstract description 5
- 206010003445 Ascites Diseases 0.000 claims abstract description 4
- 230000009483 enzymatic pathway Effects 0.000 claims abstract description 4
- 238000001668 nucleic acid synthesis Methods 0.000 claims abstract description 4
- 210000002381 plasma Anatomy 0.000 claims abstract description 4
- 210000004910 pleural fluid Anatomy 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims abstract description 3
- 239000008280 blood Substances 0.000 claims abstract description 3
- 101710100179 UMP-CMP kinase Proteins 0.000 claims description 37
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 claims description 37
- 102100037357 Thymidylate kinase Human genes 0.000 claims description 29
- 238000003556 assay Methods 0.000 claims description 20
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 18
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 13
- 108010000742 dTMP kinase Proteins 0.000 claims description 13
- 230000002538 fungal effect Effects 0.000 claims description 12
- 239000007790 solid phase Substances 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 210000004962 mammalian cell Anatomy 0.000 claims description 11
- 210000005253 yeast cell Anatomy 0.000 claims description 10
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 239000004033 plastic Substances 0.000 claims description 9
- 229920003023 plastic Polymers 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- JSVCNGIOSXNCRF-YGOYTEALSA-N 1-[(2s,4s,5r)-2-ethenyl-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C=C)O[C@H](CO)[C@@H](O)C1 JSVCNGIOSXNCRF-YGOYTEALSA-N 0.000 claims description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000011504 assay standardization Methods 0.000 claims description 2
- 102100032947 UMP-CMP kinase 2, mitochondrial Human genes 0.000 claims 15
- 229940041514 candida albicans extract Drugs 0.000 abstract description 12
- 239000012138 yeast extract Substances 0.000 abstract description 12
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 abstract description 8
- 238000011534 incubation Methods 0.000 abstract description 7
- -1 new drug candidates Chemical class 0.000 abstract description 7
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 abstract description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract description 5
- 229940104230 thymidine Drugs 0.000 abstract description 5
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 235000021317 phosphate Nutrition 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 23
- 101710102179 Thymidylate kinase Proteins 0.000 description 17
- 239000013615 primer Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 12
- 230000002285 radioactive effect Effects 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 8
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 102100038358 Prostate-specific antigen Human genes 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 5
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 229960002555 zidovudine Drugs 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- 238000006209 dephosphorylation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003547 immunosorbent Substances 0.000 description 3
- 150000004712 monophosphates Chemical class 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102100025677 Alkaline phosphatase, germ cell type Human genes 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108700020962 Peroxidase Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 102000005497 Thymidylate Synthase Human genes 0.000 description 2
- WXFYBFRZROJDLL-RRKCRQDMSA-N [(2r,3s,5r)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(I)=C1 WXFYBFRZROJDLL-RRKCRQDMSA-N 0.000 description 2
- OIFWQOKDSPDILA-XLPZGREQSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 OIFWQOKDSPDILA-XLPZGREQSA-N 0.000 description 2
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 108010011219 dUTP pyrophosphatase Proteins 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010036901 thymidine kinase 1 Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- HLXHCNWEVQNNKA-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-inden-2-amine Chemical compound COC1=CC=C2CC(N)CC2=C1 HLXHCNWEVQNNKA-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000724328 Alfalfa mosaic virus Species 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 244000255890 Biophytum sensitivum Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108030003689 Deoxynucleoside kinases Proteins 0.000 description 1
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000205180 Thermococcus litoralis Species 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- ADAWJVAGMVNRID-MYINAIGISA-N [(2r,3s,5s)-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-5-iodooxolan-2-yl]methyl dihydrogen phosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@]1(I)N1C(=O)NC(=O)C=C1 ADAWJVAGMVNRID-MYINAIGISA-N 0.000 description 1
- MCNGPQRQMPMJSB-MYINAIGISA-N [(2r,3s,5s)-5-bromo-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@]1(Br)N1C(=O)NC(=O)C=C1 MCNGPQRQMPMJSB-MYINAIGISA-N 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- BLQCQNFLEGAHPA-RRKCRQDMSA-N [[(2r,3s,5r)-5-(5-bromo-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(Br)=C1 BLQCQNFLEGAHPA-RRKCRQDMSA-N 0.000 description 1
- LBZXELUWKIEZEQ-MYINAIGISA-N [[(2r,3s,5s)-5-bromo-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@]1(Br)N1C(=O)NC(=O)C=C1 LBZXELUWKIEZEQ-MYINAIGISA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003764 chromatophore Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 108010010684 deoxyribonucleoside kinases Proteins 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0500432-0 | 2005-02-25 | ||
SE0500432 | 2005-02-25 | ||
PCT/SE2006/000246 WO2006091158A1 (en) | 2005-02-25 | 2006-02-24 | A method and kit for determination of thymidine kinase activity and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008531012A JP2008531012A (ja) | 2008-08-14 |
JP5227034B2 true JP5227034B2 (ja) | 2013-07-03 |
Family
ID=36927697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007556999A Active JP5227034B2 (ja) | 2005-02-25 | 2006-02-24 | チミジンキナーゼ活性の測定のための方法およびキットならびにその使用 |
Country Status (22)
Country | Link |
---|---|
US (2) | US8765378B2 (pt) |
EP (1) | EP1856275B1 (pt) |
JP (1) | JP5227034B2 (pt) |
KR (1) | KR101275585B1 (pt) |
CN (1) | CN101128600B (pt) |
AT (1) | ATE439451T1 (pt) |
AU (1) | AU2006217129B2 (pt) |
BR (1) | BRPI0609044B8 (pt) |
CA (1) | CA2598726C (pt) |
DE (1) | DE602006008435D1 (pt) |
DK (1) | DK1856275T3 (pt) |
EA (1) | EA012438B1 (pt) |
ES (1) | ES2330881T3 (pt) |
HK (1) | HK1117197A1 (pt) |
IL (1) | IL185425A (pt) |
MX (1) | MX2007010334A (pt) |
NO (1) | NO341196B1 (pt) |
NZ (1) | NZ556764A (pt) |
PL (1) | PL1856275T3 (pt) |
PT (1) | PT1856275E (pt) |
WO (1) | WO2006091158A1 (pt) |
ZA (1) | ZA200707334B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011142719A1 (en) * | 2010-05-14 | 2011-11-17 | Staalhandske Per | Kit and method |
US8728751B2 (en) * | 2011-04-12 | 2014-05-20 | Veterinary Diagnostics Institute, Inc. | System and method for diagnosing lymphoma in cats |
WO2013048952A1 (en) * | 2011-09-28 | 2013-04-04 | Biomed Valley Discoveries, Inc. | Methods and compositions for detecting infections |
CN103728456B (zh) * | 2013-09-16 | 2015-09-30 | 长沙赢润生物技术有限公司 | 胸腺嘧啶核苷激酶的elisa诊断试剂盒 |
CN106556592B (zh) * | 2015-09-24 | 2019-05-21 | 深圳市安群生物工程有限公司 | 定量检测人tk1的化学发光试剂盒及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE453514B (sv) * | 1982-05-14 | 1988-02-08 | Gronowitz Jan Sim0N | Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning |
SE462497B (sv) * | 1988-11-30 | 1990-07-02 | Clas Fredrik Runesson Kaelland | Saett foer att aktivitetsbestaemma polymeraser |
KR100396548B1 (ko) * | 2001-01-10 | 2003-09-03 | 삼성전자주식회사 | 프린팅 속도를 향상시키는 프린터 제어 장치 및 그 방법 |
BRPI0210359B8 (pt) * | 2001-06-14 | 2021-07-27 | Cavidi Tech Ab | método para medir a polimerização de dna dependente do dna em uma amostra biológica, e, embalagem comercial |
WO2004011627A2 (en) * | 2002-07-25 | 2004-02-05 | David-Nicolas Chaperon | A recombinant host cell line screening system for drugs with potential anti-cancer and anti-(retro-) viral activity |
DE60217665T2 (de) * | 2002-07-27 | 2007-10-11 | Diasorin Ab | Verfahren zur Bestimmung der Aktivität von Thymidinkinase-1 und dessen Verwendung |
EP1627230B1 (en) * | 2003-05-16 | 2010-09-15 | AroCell AB | Predicting cancer progression |
DE102004032872A1 (de) * | 2004-07-01 | 2006-01-19 | Bayer Cropscience Ag | Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Thymidylat-Kinasen |
-
2006
- 2006-02-24 AU AU2006217129A patent/AU2006217129B2/en active Active
- 2006-02-24 NZ NZ556764A patent/NZ556764A/en unknown
- 2006-02-24 ZA ZA200707334A patent/ZA200707334B/xx unknown
- 2006-02-24 JP JP2007556999A patent/JP5227034B2/ja active Active
- 2006-02-24 BR BRPI0609044A patent/BRPI0609044B8/pt active IP Right Grant
- 2006-02-24 ES ES06716936T patent/ES2330881T3/es active Active
- 2006-02-24 KR KR1020077019117A patent/KR101275585B1/ko active IP Right Grant
- 2006-02-24 WO PCT/SE2006/000246 patent/WO2006091158A1/en active Application Filing
- 2006-02-24 PT PT06716936T patent/PT1856275E/pt unknown
- 2006-02-24 US US11/883,187 patent/US8765378B2/en active Active
- 2006-02-24 EP EP06716936A patent/EP1856275B1/en active Active
- 2006-02-24 AT AT06716936T patent/ATE439451T1/de active
- 2006-02-24 MX MX2007010334A patent/MX2007010334A/es active IP Right Grant
- 2006-02-24 CA CA2598726A patent/CA2598726C/en active Active
- 2006-02-24 PL PL06716936T patent/PL1856275T3/pl unknown
- 2006-02-24 CN CN200680005892.8A patent/CN101128600B/zh active Active
- 2006-02-24 DK DK06716936T patent/DK1856275T3/da active
- 2006-02-24 DE DE602006008435T patent/DE602006008435D1/de active Active
- 2006-02-24 EA EA200701572A patent/EA012438B1/ru unknown
-
2007
- 2007-08-21 IL IL185425A patent/IL185425A/en active IP Right Grant
- 2007-09-25 NO NO20074882A patent/NO341196B1/no unknown
-
2008
- 2008-07-22 HK HK08108068.2A patent/HK1117197A1/zh unknown
-
2014
- 2014-05-23 US US14/286,130 patent/US9376707B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9376707B2 (en) | Kit for determination of thymidine kinase activity and use thereof | |
Kowluru et al. | Localization and characterization of the mitochondrial isoform of the nucleoside diphosphate kinase in the pancreatic β cell: evidence for its complexation with mitochondrial succinyl-CoA synthetase | |
AU2016350141B2 (en) | Methionine adenosyltransferase biological activity assay method and reagent kit | |
JPH10511260A (ja) | 個々のタンパクキナーゼ活性の定量法 | |
Dehde et al. | Two immunologically distinct human DNA polymerase α-primase subpopulations are involved in cellular DNA replication | |
EP0877940A1 (en) | Methods for the early detection of hiv infection | |
US20140273036A1 (en) | Luminescent detection of inorganic phosphate and coupled reactions | |
WO2008024052A1 (en) | A method and a kit for determination of an enzyme activity involved in metabolic production of a deoxynucleoside triphosphate and use thereof | |
Orfanos et al. | A rapid screening test for Duchenne muscular dystrophy using dried blood specimens | |
JP5875096B2 (ja) | 蛍光又は吸光度の検出方法、バックグラウンド抑制方法、adpの測定方法、adpを生成する酵素の活性測定方法、及び糖転移酵素の活性測定方法 | |
JP4828752B2 (ja) | サイクリン/cdk複合体のリン酸化酵素活性測定方法 | |
JP6522466B2 (ja) | オートタキシンの活性測定方法 | |
Garforth et al. | Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptase | |
FI77895C (fi) | Foerfarande foer bestaemning av deoxithymidinkinas-isoentsymaktivitet och dess anvaendning foer diagnosis av sjukdomar. | |
US20190212340A1 (en) | An elisa-like assay for quantifying enzymatic activities of mono-adp-ribosyltransferases | |
WO1998042869A1 (en) | Mammalian dna primase screens and activity modulating agents | |
JP2005245403A (ja) | アポトーシス調節活性を測定する方法、及びアポトーシス調節活性を有する化合物のスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090224 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5227034 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160322 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |